Capricor Plunges 10.03% Amid Fraud Lawsuits

On August 11, 2025, Capricor's stock experienced a significant drop of 10.03% in pre-market trading, reflecting a notable decline in investor sentiment.

Capricor Therapeutics, Inc. is currently facing multiple securities fraud lawsuits, which have contributed to the recent decline in its stock price. The Schall Law Firm, along with other legal entities, has filed class action lawsuits against the company, alleging violations of the Securities Exchange Act of 1934. These lawsuits claim that Capricor made false and misleading statements regarding its deramiocel drug candidate, particularly concerning its progress towards FDA approval and the concealment of adverse data from the Phase 2 HOPE-2 trial.

Investors who purchased Capricor's securities between October 9, 2024, and July 10, 2025, are encouraged to participate in these lawsuits to recover their losses. The legal actions highlight the potential risks associated with investing in biotech companies, especially those with ongoing clinical trials and regulatory approval processes. The outcome of these lawsuits could have a significant impact on Capricor's future operations and investor confidence.